Skip to main content
Journal cover image

Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.

Publication ,  Journal Article
Alderman, EL; Levy, JH; Rich, JB; Nili, M; Vidne, B; Schaff, H; Uretzky, G; Pettersson, G; Thiis, JJ; Hantler, CB; Chaitman, B; Nadel, A
Published in: J Thorac Cardiovasc Surg
November 1998

OBJECTIVE: We examined the effects of aprotinin on graft patency, prevalence of myocardial infarction, and blood loss in patients undergoing primary coronary surgery with cardiopulmonary bypass. METHODS: Patients from 13 international sites were randomized to receive intraoperative aprotinin (n = 436) or placebo (n = 434). Graft angiography was obtained a mean of 10.8 days after the operation. Electrocardiograms, cardiac enzymes, and blood loss and replacement were evaluated. RESULTS: In 796 assessable patients, aprotinin reduced thoracic drainage volume by 43% (P < .0001) and requirement for red blood cell administration by 49% (P < .0001). Among 703 patients with assessable saphenous vein grafts, occlusions occurred in 15.4% of aprotinin-treated patients and 10.9% of patients receiving placebo (P = .03). After we had adjusted for risk factors associated with vein graft occlusion, the aprotinin versus placebo risk ratio decreased from 1.7 to 1.05 (90% confidence interval, 0.6 to 1.8). These factors included female gender, lack of prior aspirin therapy, small and poor distal vessel quality, and possibly use of aprotinin-treated blood as excised vein perfusate. At United States sites, patients had characteristics more favorable for graft patency, and occlusions occurred in 9.4% of the aprotinin group and 9.5% of the placebo group (P = .72). At Danish and Israeli sites, where patients had more adverse characteristics, occlusions occurred in 23.0% of aprotinin- and 12.4% of placebo-treated patients (P = .01). Aprotinin did not affect the occurrence of myocardial infarction (aprotinin: 2.9%; placebo: 3.8%) or mortality (aprotinin: 1.4%; placebo: 1.6%). CONCLUSIONS: In this study, the probability of early vein graft occlusion was increased by aprotinin, but this outcome was promoted by multiple risk factors for graft occlusion.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Thorac Cardiovasc Surg

DOI

ISSN

0022-5223

Publication Date

November 1998

Volume

116

Issue

5

Start / End Page

716 / 730

Location

United States

Related Subject Headings

  • Veins
  • Survival Rate
  • Risk Factors
  • Respiratory System
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans
  • Heparin
  • Hemostatics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Alderman, E. L., Levy, J. H., Rich, J. B., Nili, M., Vidne, B., Schaff, H., … Nadel, A. (1998). Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg, 116(5), 716–730. https://doi.org/10.1016/S0022-5223(98)00431-0
Alderman, E. L., J. H. Levy, J. B. Rich, M. Nili, B. Vidne, H. Schaff, G. Uretzky, et al. “Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.J Thorac Cardiovasc Surg 116, no. 5 (November 1998): 716–30. https://doi.org/10.1016/S0022-5223(98)00431-0.
Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg. 1998 Nov;116(5):716–30.
Alderman, E. L., et al. “Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.J Thorac Cardiovasc Surg, vol. 116, no. 5, Nov. 1998, pp. 716–30. Pubmed, doi:10.1016/S0022-5223(98)00431-0.
Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, Uretzky G, Pettersson G, Thiis JJ, Hantler CB, Chaitman B, Nadel A. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg. 1998 Nov;116(5):716–730.
Journal cover image

Published In

J Thorac Cardiovasc Surg

DOI

ISSN

0022-5223

Publication Date

November 1998

Volume

116

Issue

5

Start / End Page

716 / 730

Location

United States

Related Subject Headings

  • Veins
  • Survival Rate
  • Risk Factors
  • Respiratory System
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans
  • Heparin
  • Hemostatics